csl limited - gmsnetgmsnet.kr/kor/grobal_research/1.csl-limited.pdf · unique visitors graph basic...
TRANSCRIPT
Company Description
CSL Limited is a global, specialty biopharmaceutical company that researches, develops, manufactures and markets products to treat and preventserious human medical conditions.
The CSL Group has a combined heritage of outstanding contribution to medicine and human health with more than 90 years experience in thedevelopment and manufacture of vaccines and plasma protein biotherapies. With major facilities in Australia, Germany, Switzerland and the US,CSL has over 11000 employees working in 27 countries.
Unique Visitors Graph www.csl.com.au Basic Information
CSL Limitedhttp://www.csl.com.au45 Poplar RoadParkville, Victoria3052Australia+61-393891911+61-39389143410411$4.87B28360000Biological Products, Except Diagnostic
Company Name -Web -
Address -City, State -
Zip Code -Country -
Phone Number -Fax Number -Employees -
Revenue -SIC Code -
Industry -
CSL Limited
Links & Statistics – Social Media
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Company Type -County -
Location Type -Country -
Accountant -D-U-N-S Number -
Is Subsidiary -Manufacturer -
Exchange -Symbol -
Year of Founding -Fiscal Year – End -
2013 Sales -
Public--HeadquartersAustraliaErnst & Young753243823No--ASXCSL1916June$4.87B
1 Year Sales Growth (%) -Total Assets (US Dollars, Million) -
Primary NAICS Code -Market Value -
Prescreen Score -Tradestyle -
2013 Employees Total -Employees (This Site) -
1-Year Employee Growth -2013 Net Income -
1-Year Net Income Growth -Latitude/Longitude -
ASX Rank (June 2013) -
8.24%$5.88B325414----CSL LTD PAYG BRANCH10,411--4.19%$1.20B19.98%-37.778815/144.94271250
Credit Rating Score
The information 360°Profiles provides should be considered primarily as indicators. The firmographicand industry details such as number of employees, industry report and entry barriers should be takenonly as an initial reference. We suggest that this information not be used exclusively while makingcredit decisions and that consultation with trade references, banks, credit bureaus and otherauthorized institutions is obtained. We are not finance advisors and do not warrant thecompleteness, timeliness or accuracy of rating codes, and will not be responsible for losses incurredwith the use of this information.
Corporate Information
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Worldwide Locations
Argentina
Regional Sales OfficeFray Justo Sarmiento 2350B1636AKJ - OlivosBs.As.-ArgentinaPhone: +54 11 4344-9550Fax: +54 11 4344-9577/9578
Austria
Regional Sales OfficeAltmannsdorfer Strasse 104A-1121 ViennaAustriaPhone: +43 1 801 01 2463Fax: +43 1 801 01 2810
Belgium
Regional Sales OfficeTechnologielaan 13 B-3001 Leuven BelgiumPhone: +32-16-38-80-80Fax: +32-16-38-80-89
Brazil
Regional Sales OfficeR. Olimpíadas, 1349th floor - Vila OlimpiaSão Paulo - SP - Brasil Phone: + 55-0800-6008810Fax: + 55-11-3525-5828/ 5829
Canada
Regional Sales Office55 Metcalfe StreetOttawa, Ontario K1P 6L5CanadaPhone: +613-232-3111Fax: +613-232-5031
Denmark
Regional Sales OfficeLyngby Hovedgade 70B, 1 t.v.DK-2800 Kgs. Lyngby DenmarkPhone: +45 4520 1420Fax: +45 4520 1425
France
Regional Sales Office44 rue Cambronne75015 ParisFrancePhone: +33-1-53-58-54-00Fax:+33-1-53-58-54-05
Greece
Regional Sales Office35 Michalacopoulou Str.11528 AthensGreecePhone: +30-210- 72-55-660,1Fax:+30-210-72-55-663
China
Hong KongUnit 4205, AIA Tower183 Electric RoadNorth PointHong KongPhone: +852-2979-6126Fax: +852-2880-5952
ShanghaiRoom 2101,2111, The Center989 Changle RoadShanghai People's Republic of ChinaPhone: +852-5407-5080Fax: +8621-5407-5280
BeijingRm 1623, Tower 2, Bright China Chang An Building7 Jianguomennei AveDongcheng DistrictBeijing People's Republic of ChinaPhone: +8610-6510-2533Fax: +8621-6510-2529
GuangzhouUnit 4005-06, Onelink Center230 Tianhe RoadGuangzhou 510620, People's Republic of ChinaPhone: +8620-3833-1233Fax: +8620-3833-1391
ChengduRoom 1805, International LandNo.11 Section 4Renmin South Road,ChengDu 610041, People's Republic of ChinaPhone: +8628-8528-3021Fax: +8628-8528-4068
WuhanRm 2303, Tower A, New World Center634 Jiefang AvenueHankou Wuhan People's Republic of ChinaPhone: +8627-8359-0686Fax: +8627-8359-0603
Germany
Regional Sales OfficePhilipp-Reis-Strasse 265795 Hattersheim am MainPhone: +49-69-305-17152Fax:+49-69-305-81045
Research and DevelopmentEmil-von-Behring-Strasse 76 35041 Marburg Phone: +49-6421-39-12 Fax: +49-6421-39-4825
Manufacturing SiteEmil-von-Behring-Strasse 76 35041 Marburg Phone: +49-6421-39-12 Fax: +49-6421-39-4825
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Worldwide Locations
Hong Kong
CSL Biotherapies Asia Pacific Ltd4205-4208 AIA Tower183 Electric RoadNorth Point, Hong KongPhone: +852-2880-5333Fax:+852-2880-5952
Italy
Regional Sales OfficeCSL Behring SpA P. S.Tuerr, 5 , I - 20149 Milan ItalyPhone: + 39 02 34964 1 Fax:+ 39 02 34964 261
Japan
Regional Sales OfficeKDX Toyosu Grandsquare1-7-12 Shinonome, Koto-kuTokyo 135-0062 JapanPhone: +81-3-3534-5831 Fax:+81-3-3534-5861
Malaysia
CSL Biotherapies AsiaUnits 1206-08 12/F K. Wah Ctr.191 Java Road, North Point Hong KongPeople's Republic of ChinaPhone: +852-2880-5333Fax:+852-2880-5457 / 5952
Mexico
Regional Sales OfficeSierra Mojada 626 Col. Lomas de Barrilaco C.P. 11010 Mexico D.F.Mexico Phone: +52-30-98-03-00Fax:+52-30-98-03-04
Netherlands
Regional Sales OfficeBijster 144817 HX BredaNederlandPhone: +31 (0)85 111 96 00Fax: +31 (0)85 111 99 60
New Zealand
CSL Biotherapies (NZ) LtdCentral Park666 Great South RoadPenroseAuckland
P.O. Box 62590Central ParkAuckland
Phone: +64 9 579 8105Freephone: 0800 502 757Fax: +64 9 579 8106Free fax: 0800 920 054
Portugal
Regional Sales OfficeLda. Av. 5º. de Outubro, 198 - 3º Esqº, 1050 064 Lisbon, Portugal Phone: +351-21-782-62-30 Fax:+351-21-782-62-36
Spain
Regional Sales OfficeCSL Behring, S.A.Av. dels Països Catalans, 34, 3ª planta, 08950 Esplugues de Llobregat, SpainPhone: +34-93-367-1870 Fax: +34-93-367-1868
Sweden
Regional Sales OfficeBerga Backe 2 182 17 Danderyd, SwedenPhone: +46-8-544-966-70 Fax:+46-8-622-68-38
United Kingdom
Regional Sales OfficeCSL Behring UK Ltd Market Place Hayworth House Haywards Heath West Sussex, RH16 1DB, UK Phone: +44(0)1444 447 400 Fax:+44(0)1444 447 401
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Worldwide Locations
United States
Corporate Headquarters1020 First Avenue PO Box 61501 King of Prussia, PA 19406-0901 USA Phone: +1 610-878-4000 Fax: +1 610-878-4009
CSL Plasma5201 Congress AvenueSuite 220Boca Raton, Florida 33487USA Phone: +1-561-981-3700Fax: +1-561-912-3005
Regional Sales Office1020 First Avenue PO Box 61501 King of Prussia, PA 19406-0901 USA Phone: +1 610-878-4000 Fax: +1 610-878-4009
Research and Development1020 First Avenue PO Box 61501 King of Prussia, PA 19406-0901 USA Phone: +1 610-878-4000 Fax: +1 610-878-4009
Research and DevelopmentP.O. Box 511Kankakee, Illinois 60901 USA Phone: +1-815-932-6771Fax: +1-815-932-2216
Manufacturing SiteP.O. Box 511Kankakee, Illinois 60901 USA Phone: +1-815-932-6771Fax: +1-815-932-2216
Switzerland
Bern Regional Sales OfficeWankdorfstrasse 10 CH-3000 Bern 22 Switzerland Phone: +41-31-344-4444 Fax:+41-31-344-5555
Zurich Regional Sales OfficeHerostrasse 7 CH-8048 Zurich Switzerland Phone: +41-44431-5858 Fax:+41-44431-5860
Research and DevelopmentWankdorfstrasse 10 CH-3000 Bern 22 Switzerland Phone: +41-31-344-4444 Fax:+41-31-344-5555
Manufacturing SiteWankdorfstrasse 10 CH-3000 Bern 22 Switzerland Phone: +41-31-344-4444 Fax:+41-31-344-5555
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Company History
The Commonwealth Serum Laboratories was established in Australia in 1916 to service the health needs of a nation isolated by war. CSL Limitedwas then incorporated in 1991 and listed on the Australian Stock Exchange in 1994.
Since then CSL acquired a number of businesses including CSL Behring. CSL Behring can trace its corporate roots back to Emil von Behring, aninnovator with serum therapies who won the first Nobel Prize in Physiology and Medicine.
1901 - Emil von Behring wins first Nobel Prize in MedicineGerman doctor Emil von Behring wins the first Nobel Prize in Physiology/Medicine for his work on serum therapies. Von Behring’s pioneering workresults in the modern methods of immunization that have largely eradicated diphtheria worldwide. In 1904 von Behring establishes Behringwerketo produce sera and vaccine products.
1915 - Plan to Establish Federal Serum Institute AnnouncedExperience during World War I makes it clear that Australia cannot afford to rely on overseas supplies of important sera and vaccines. Thecountry was effectively cut off from its traditional sources of vaccines and other bacteriological products for the duration of the war.
1916 - CSL EstablishedThe Commonwealth Serum Laboratories (CSL) are established to supply Australia with vaccines and other bacteriological products.Dr William Penfold, a bacteriologist at Britain's Lister Institute of Preventative Medicine, is appointed as CSL's founding Director.
1917 - Temporary LocationThe Walter and Eliza Hall Institute of Medical Research (WEHI) provides CSL with free accommodation in its building in Lonsdale Street,Melbourne, until a permanent home can be found. Collaboration between the two organisations continues to this day.
1918 - CSL Moved to Permanent SiteCSL transfers operations from its temporary base at WEHI to its permanent site in Parkville, Melbourne.
In 1918 Melbourne and Sydney's ports have been placed under quarantine in an attempt to avoid the introduction into Australia of the "SpanishInfluenza" epidemic which is claiming thousands of lives around the world. One of CSL's first actions is to prepare advance doses of a vaccine incase an Australia outbreak of the epidemic occurs.
1919 - Spanish Flu Pandemic in AustraliaSample of the vaccine produced by the Commonwealth Serum Laboratories to combat the 1919 Influenza EpidemicCSL's first challenge is theInfluenza Epidemic of 1919 - the "Spanish 'Flu". When the epidemic reaches Australia in January 1919, public health authorities respond byclosing cinemas, theatres, racecourses and schools. Masks are required of anyone moving through the streets. Schools and kindergartens - evenMelbourne's Exhibition Building - are turned into makeshift hospitals. CSL's staff numbers are temporarily tripled as the organisation produces 3million doses of a mixed bacterial vaccine in an attempt to combat the disease.
For More Details ClickHere
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Description
CSL Limited proposes that human plasma holds the potential to save lives. The biopharmaceutical holding company operates through two mainsubsidiaries: CSL Behring develops plasma-derived and recombinant products used to treat infections, bleeding disorders, and autoimmunediseases, while CSL Biotherapies manufactures influenza vaccines that are marketed and sold globally.
CSL Biotherapies' Immunohaematology unit manufactures in-vitro diagnostic products to test blood for transfusion and to detect snake venoms.Under licenses, CSL also markets and distributes other companies' vaccines and drugs in Australia and New Zealand, such as Merck's GARDISIL(cervical cancer) and Crucell's Vivotif Oral (typhoid).
CSL Limited makes revenues from three different segments: plasma products developed, made, and marketed by CSL Behring (human plasma isculled from a network of collection centers in the US and Germany through CSL Behring's subsidiary CSL Plasma); other human healthproducts, including those developed and made by CSL Biotherapies; and intellectual property licensed to third parties. Although the group'sresearch and development, manufacturing, sales, and distribution operations are spread throughout the world, it operates predominantly in fourgeographic areas, namely Australia, Germany, Switzerland, and its largest market, the US.
CSL Behring is the company's largest segment, with immunoglobulins (used to treat infections and autoimmune diseases) showing the mostgrowth across that subsidiary's product portfolio. Privigen, an intravenous immunoglobulin for patients with primary immune deficiency, is one ofits leading products. Other approved products include therapies for haemophilia and coagulation disorders, hereditary angioderma, and inheritedrespiratory disease.
CSL Biotherapies runs one of the world's largest manufacturing facilities for producing influenza vaccines. Using the same technology its uses toproduce seasonal flu vaccines, CSL manufactures a pandemic H1N1 swine flu vaccine called Panvax. Sales are achieved through supply contractswith Australia, Canada, Germany, Singapore, and the US. A portion of the vaccine was also donated to the World Health Organization.
CSL has established and continues to maintain strong research and development operations. It has long-standing partnerships with othercompanies and academic institutions in Australia, Asia, Europe, and North America. It is also capable of manufacturing complex R&Dbiopharmaceuticals and overseeing the safety profiles of its products. CSL's strategy is to build an R&D portfolio of candidates particularly in theareas of coagulation, immunology, inflammation, and oncology.
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Businesses
With major facilities in Australia, Germany, Switzerland and the U.S., CSL has over 10,000 employees working in 27 countries.For many serious and life-saving medical products, we are a partner of choice for many companies around the world.
Headquarters in Melbourne Australia, the CSL Group includes:
bioCSL incorporating Immunohaematology CSL Behring incorporating CSL Plasma
Research and Development
In 2006/07, we invested over AUD$190m in this part of our business. Our centres of excellence are located around the world and they focus on: -
Developing new products Improving existing products
Plasma products
CSL is a leading manufacturer in a US$7.5 billion plasma industry. A continual focus on innovation in new products, improved products andmanufacturing know how is the key to future growth.
The key businesses involved with plasma products include: -
CSL Behring is a global provider of plasma-derived & recombinant products. We operate one of the world's largest plasma collectionnetworks through CSL Plasma
CSL Behring is the chosen national plasma fractionator of Australia, New Zealand, Hong Kong, Malaysia, Singapore and Taiwan.
Vaccines and pharmaceuticals
CSL is also a major manufacturer in a US$2 billion influenza industry, with 40 years manufacturing experience and sales spanning 27 countriesaround the globe.
In addition to providing influenza vaccines worldwide, bioCSL manufactures, sells and distributes a comprehensive range of vaccines,antivenoms and other pharmaceutical products in Australia and New Zealand. We also manufacture and market in vitro diagnostic productsthrough Immunohaematology.
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Products
MarketDevelopment
New Product Development
MarketDevelopment
New Product Development
Life Cycle Management
Market Development
Research/Pre-Clinical Clinical Development Registration/Post Launch
For More Details ClickHere
CSL Research and Development Investment (US$ Millions)
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Awards & Recognition
CSL Limited has been recognised as one of Australia’s most outstanding equal opportunity employers by the FederalGovernment for its work in establishing an innovative onsite childcare centre at its corporate headquarters in Melbourne.
The company today received the Minister’s Award for Outstanding Equal Employment Opportunity Initiative for its recently-opened Thinking Kids Children’s Centre, a purpose-built, architecturally-designed facility offering 114 places for childrenaged up to six years located at its Parkville, Melbourne, site.
The annual award, presented by Federal Minister for the Status of Women, Kate Ellis, at a luncheon in Sydney, recognisesorganisations that implement outstanding strategic initiatives aimed at effectively addressing issues related to equalemployment opportunity for women.
The centre, which opened on September 19, provides priority access to CSL employees, with places also available to thewider community.
CSL Biotherapies Executive Vice President Dr Jeff Davies, accepting the award on behalf of CSL, said women represented51% of the CSL Australian workforce and brought enormous value to the business.
―We know that to continue to attract and retain talented women, we must provide a supportive and inclusive workplace and minimise the barriersto career progression,‖ Dr Davies said.
CSL’s work to establish the centre started over five years ago when internal research indicated that an onsite childcare facility would strengthenmaternity leave retention and enhance the company’s offering to potential new employees.
Equal Opportunity in the Workplace Agency Director (EOWA) Helen Conway, today congratulated CSL for providing the $4.8 million childcarecentre.
―This facility is a boon to employees who may have had to postpone their careers once they became caregivers, due to a lack of access toadequate childcare. CSL and its people will continue to gain from this important investment,‖ said Ms Conway.
The facility has proven extremely popular among CSL’s workforce in the months since its opening. Early Childhood Management Services, whichCSL has appointed to run the centre, reports that 63 children of company employees are registered for places this year.
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Press Releases
For More Media Releases ClickHere
August 14, 2013Full Year Results announcement for 2012/13
Melbourne, Australia — 14/08/2013CSL Limited (ASX:CSL) today announced a net profit after tax (NPAT) of US$1,216 million for the twelve months ended 30 June 2013, up US$192 million or 19% on a reported basis when compared to the prior comparable period (PCP). The result included an unfavourable foreign exchange impact of US$18 million. On a constant currency1 basis, net profit after tax grew 21%, slightly ahead of guidance. Earnings per share grew 24%, benefiting from current and past capital management initiatives.
Download this release:CSL Full Year results announcement for 2012/13. For More ClickHere
Additional resources:The Webcast, Analyst presentation and Full Year information is also available. More ClickHere
For further information, please contact:
Investors: Mark DehringHead of Investor RelationsCSL LimitedPhone: +613 9389 2818Email: [email protected]
Tim DuncanHintons & AssociatesPhone: +613 9600 1979Mobile: +614 0844 1122Email: [email protected]
Media:Sharon McHaleSenior Director Public AffairsCSL LimitedPhone: +613 9389 1506Mobile: +614 0997 8314Email: [email protected]
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
CSL Limited
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Company Type -Fiscal Year-End -
2013 Sales -1-Year Sales Growth -
2013 Net Income -1-Year Net Income -
Auditor -Company Website -
Public, HeadquartersJune$4.87B8.24%$1.20B19.98%Ernst & Younghttp://www.csl.com.au
Accounting Expenses -Advertising Expenses -
Contract Labor Expenses -Insurance Expenses -
Legal Expenses -Management / Administration Expenses -Office Equipment & Supplies Expenses -
Package & Container Expenses -Payroll & Benefits Expenses -
Purchased Print Expenses -Rent & Leasing Expenses -
Technology Expenses -Telecommunications Expenses -
Utilities Expenses -
Above $5,000$12,000+$50,000+Above 16 Million$5000+5 Million+25 Million+$25,000+9 Million+$3000+$4.5 Million+Above 30 Million$20,000$14,000
Revenue Vs Net Income Revenue Vs Cash Flow
Financial Overview & Business Expenditure
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Annual Income Statement
Employees
RevenueJun 13 Jun 12 Jun 11 Jun 10 Jun 09
Revenue 4,874.61 4,503.69 4,436.71 3,815.52 3,718.71
Cost of Goods Sold 2,354.79 2,330.17 2,255.54 1,870.89 1,930.57
Gross Profit 2,519.82 2,173.52 2,181.17 1,944.63 1,788.14
Gross Profit Margin 51.69% 48.26% 49.16% 50.97% 48.08%
SG&A Expense -- -- -- -- --
Depreciation & Amortization -- -- -- -- --
Operating Income 1,315.55 1,082.34 1,142.76 1,050.24 792.06
Operating Margin 26.99% 24.03% 25.76% 27.53% 21.30%
Nonoperating Income 129.39 153.81 126.65 130.98 285.69
Nonoperating Expenses -18.02 2.03 14.7 19.12 1.23
Income Before Taxes 1,444.93 1,236.15 1,269.41 1,181.23 1,101.96
Income Taxes 247.26 237.92 272.84 279.63 180.06
Net Income After Taxes 1,197.68 998.22 996.57 901.6 921.9
Continuing Operations 1,197.68 998.22 996.57 901.6 921.9
Discontinued Operations 0 0 0 0 0
Total Operations 1,197.68 998.22 996.57 901.6 921.9
Total Net Income 1,197.68 998.22 996.57 901.6 921.9
Net Profit Margin 24.57% 22.16% 22.46% 23.63% 24.79%
Diluted EPS from Continuing Oper. 2.39 1.92 1.84 1.59 1.54
Diluted EPS from Total Operations 2.39 1.92 1.84 1.59 1.54
Diluted EPS from Total Net Income 2.39 1.92 1.84 1.59 1.54
Dividends Per Share 0.61 0.58 0.61 0.45 0.35
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Net Income after Taxes
Debt Ratio -
Return On Equity -
Cash -
Current Ratio -
Long-Term Debt -
Shares Outstanding -
Dividend Yield -
Dividend Payout -
Market Cap -
56.42%
39.32%
$750.53M
3.6
$1,670.43M
488.09M
--
25.55%
$27,450.50M
2013 - Year End Financials
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Growth Rates
12 Month 36 Month 60 Month
Revenue Growth 20.40% 6.20% 8.46%
EPS Growth 38.79% 12.28% 15.62%
Dividend Growth 16.86% 8.45% 16.14%
Comparison to Industry & Market
Company Industry Median Market Median
Price/Sales Ratio 6.21 7.85 1.33
Price/Earnings Ratio 25.25 45.25 19.42
Price/Book Ratio 9.95 7.36 2.11
Price/Cash Flow Ratio 23.42 40.65 9.11
Stock History
Year Stock Price ($) P/E Per Share ($)
FY High FY Low FY Close High Low Earns. Div. Book Value
Jun 2013 59.09 35 56.24 24.69 14.62 2.39 0.61 6.07
Jun 2012 40.7 26.54 40.05 21.21 13.83 1.92 0.58 6.84
Jun 2011 40.34 32.39 35.03 21.93 17.61 1.84 0.61 7.31
Jun 2010 32.16 25.06 27.9 20.28 15.81 1.59 0.45 6.57
Jun 2009 33.76 21.6 25.86 21.89 14 1.54 0.35 7.28
Jun 2008 41.48 25.36 34.29 34.05 20.81 1.22 0.3 4.9
Jun 2007 27.35 12.83 24.89 10.91 5.12 2.51 0.18 10.52
Jun 2006 14.31 8.08 13.08 30.4 17.16 0.47 0.14 7.98
Jun 2005 9.01 5.62 8.56 4.26 2.66 2.11 0.11 8.34
Jun 2004 5.44 2.82 5.13 6.42 3.33 0.85 0.08 7.28
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Market Data & Operations
2010 Sales
% of total
US 39
Germany 15
Australia 14
Switzerland 4
Other countries 28
Total 100
2010 Sales
% of total
CSL Behring 77
Other human health (including CSL Biotherapies)
21
Intellectual property licensing
2
Total 100
Market Data
Last Close 23-Aug-2013 AUD66.20
52-Week High AUD68.00
52-Week Low AUD41.60
60-Month Beta 0.38
Market Cap AUD32,245.95 M
Shares Outstanding 487.10M
Dividend Rate AUD0.68
Divident Yield --
# of Institutional Holders 444
Latest Short Interest Ratio --
Price/Sales Ratio 6.21
Price/Book Ratio 9.95
Price/Earnings Ratio 25.25
Price/Cash Flow Ratio 23.42
Return On Assets 21.39%
Return On Equity 39.32%
Current Ratio --
Long-Term Debt/Equity --
% Owned By Institutions 23.18%
Latest Net Insider Trans. --
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Annual Cash Flow Statement
Jun 13 Jun 12 Jun 11 Jun 10 Jun 09
Cash & Cash Equivalents at the Beginning of Year 1,173.47 507.93 857.21 2,033.85 673.88
Net Cash Provided in Operating Activities 1,291.62 1,178.44 1,078.70 1,000.58 824.47
Net Cash Provided by Investing Activities -442.62 -314.73 -222.12 -250.86 -361.65
Net Cash Provided by Financing Activities -1,199.84 -215.78 -1,365.27 -2,014.49 848.04
Net Increase/Decrease in Cash Equivalents -350.85 647.94 -508.68 -1,264.76 1,310.87
Cash & Cash Equivalents at the End of Year 750.53 1,173.47 507.93 857.21 2,033.85
Historical Financials ( Annual Income Statement)
Year Revenue Net Income Net Profit Margin Employees
Jun 2013 $4,874.61M $1,197.68M 24.57% --
Jun 2012 $4,503.69M $998.22M 22.16% --
Jun 2011 $4,436.71M $996.57M 22.46% 10,411
Jun 2010 $3,815.52M $901.60M 23.63% 9,992
Jun 2009 $3,718.71M $921.90M 24.79% 10,340
Jun 2008 $3,416.17M $674.08M 19.73% 9,726
Jun 2007 $2,692.10M $457.65M 17.00% 8,423
Jun 2006 $2,079.42M $85.66M 4.12% 7,575
Jun 2005 $2,094.07M $416.17M 19.87% 6,474
Jun 2004 $1,138.31M $151.50M 13.31% 7,565
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Assets Jun 13 Jun 12 Jun 11 Jun 10 Jun 09
Current Assets
Cash 750.53 1,173.47 507.93 857.21 2,033.85
Net Receivables 802.33 756.44 824.88 733.31 690.97
Inventories 1,614.30 1,485.35 1,542.63 1,245.59 1,224.48
Other Current Assets 42.24 35.96 50.95 23.21 32.21
Total Current Assets 3,209.40 3,451.22 2,926.38 2,859.32 3,981.51
Net Fixed Assets 1,562.90 1,383.35 1,279.12 1,034.27 963.39
Other Noncurrent Assets 1,111.72 1,077.26 1,164.04 996.78 981.7
Total Assets 5,884.02 5,911.83 5,369.54 4,890.37 5,926.60
Liabilities Jun 13 Jun 12 Jun 11 Jun 10 Jun 09
Current Liabilities
Accounts Payable -- -- -- -- --
Short Term Debt 5.61 202.77 273.29 53.47 298.2
Other Current Liabilities 887.11 749.43 729.13 620.34 687.84
Total Current Liabilities 892.72 952.2 1,002.41 673.8 986.04
Long Term Debt 1,670.43 1,392.90 475.69 610.55 494.66
Other Noncurrent Liabilities 360.1 83.91 30.24 -3.45 51
Total Liabilities 2,923.25 2,429.02 1,508.34 1,280.90 1,531.70
Shareholder's Equity Jun 13 Jun 12 Jun 11 Jun 10 Jun 09
Preferred Stock Equity 0 0 0 0 0
Common Stock Equity 2,960.77 3,482.81 3,861.20 3,609.47 4,394.90
Total Equity 2,960.77 3,482.81 3,861.20 3,609.47 4,394.90
Shares Outstanding (M) 488.09 509.21 527.96 549.69 603.49
Balance Sheet
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Strengths Weaknesses
ThreatsOpportunities
Broad Product Portfolio.
Diversified Geographical Presence.
Legal Proceedings.
Emerging Markets.
Charging Demographics.
Stringent Government Regulations.
Uncertain R&D Outcomes.
SWOT Analysis
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Competitors Analysis
Company Name Web Address City / State / Zip Country Phone Number
Baxter International http://www.baxter.com Deerfield, IL, 60015 United States 847-948-2000
Grifols http://www.grifols.com Barcelona, 08174 Spain +34-93-571-0165
Sanofi http://www.sanofi.com Paris, 75008 France +33 (0)1 53 77 40 00
Company Gross Revenue Net Profit Margin Net Operating CashFlow
Baxter International (Top Competitor) $14,190.00M 15.47% $3,106.00M
Grifols (Top Competitor) $3,463.58M 11.40% $670.16M
Sanofi (Top Competitor) $47,517.18M 10.11% $10,797.98M
Alexion Pharmaceuticals $1,134.11M 26.54% $410.61M
Astrazeneca $27,973.00M 18.47% $6,948.00M
Bayer Ag $52,542.84M 7.28% $5,989.04M
Cangene $111.03M -7.93% ($5.66M)
Glaxosmithkline $42,693.99M 15.24% $7,066.94M
Haemonetics $891.99M 2.26% $85.07M
Hemacare $16.25M -4.96% ($2.44M)
Johnson & Johnson $67,224.00M 18.38% $15,396.00M
Merck $47,267.00M 11.44% $10,022.00M
Novartis $57,561.00M 16.42% $14,194.00M
Prometic $23.39M -2.26% ($2.14M)
Seracare Life Sciences $43.48M 4.73% $3.70M
Competitors Financial Analysis
Top Competitors Website Analysis
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Competitive Landscape
CSL Baxter International Sanofi Grifols
Annual Sales $4.87B $14.19B $47.52B $3.46B
Employees -- 51,000 1,11,974 11,108
Market Cap $27.45B $36.41B $167.92B $19.00B
CSLBaxter
InternationalSanofi Grifols
Industry Median
Market Median1
12-Month Revenue Growth 20.40% 2.14% 2.56% 45.96% 6.66% -2.51%
12-Month Net Income Growth 33.46% 4.59% -12.75% 410.24% 30.12% -8.38%
12-Month EPS Growth 38.79% 7.73% -12.82% 294.74% -- --
12-Month Dividend Growth 16.86% 24.11% 38.11% -- -- --
36-Month Revenue Growth 6.20% 4.15% 5.35% 42.11% 12.92% 6.27%
36-Month Net Income Growth 7.59% 1.80% -1.92% 20.15% 17.81% 0.87%
36-Month EPS Growth 12.28% 5.20% -2.46% 6.86% -- --
36-Month Dividend Growth 8.45% 13.63% 5.50% -- -- --
2012 Key Numbers
2012 Growth
2012 Annual Sales 2012 Net Profit Margin
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
CSLBaxter
InternationalSanofi Grifols
Industry Median
Market Median1
Days of Sales Outstanding 55.5 58.09 84.49 55.91 63.55 41.25
Inventory Turnover 1.6 2.39 1.63 1.3 1.44 7.43
Days Cost of Goods Sold In Invent. 228.6 152.56 223.35 281.66 252.76 49.11
Asset Turnover 0.87 0.68 0.34 0.46 0.48 0.31
Net Receivables Turnover Flow 6.58 6.28 4.32 6.53 5.74 8.85
Effective Tax Rate 17.11% 20.06% 14.96% 31.88% 17.40% 27.69%
CSLBaxter
InternationalSanofi Grifols
Industry Median
Market Median1
Gross Profit Margin 51.69% 51.65% 67.84% 51.18% 81.70% 33.78%
Pre-Tax Profit Margin 29.64% 19.35% 12.43% 16.53% 23.19% 9.75%
Net Profit Margin 24.57% 15.47% 10.11% 11.40% 17.67% 6.65%
Return on Equity 39.32% 32.08% 6.15% 16.24% 18.02% 10.86%
Return on Assets 21.39% 10.52% 3.48% 5.20% 8.42% 2.04%
Return on Invested Cap 25.18% 15.10% 4.24% 3.05% 10.80% 5.97%
CSLBaxter
InternationalSanofi Grifols
Industry Median
Market Median1
Price/Sales Ratio 6.21 2.77 2.96 3.92 7.85 1.33
Price/Earnings Ratio 25.25 17.89 29.24 34.48 45.25 19.42
Price/Book Ratio 9.95 5.36 1.8 5.5 7.36 2.11
Price/Cash Flow Ratio 23.42 13.99 17.21 18.38 40.65 9.11
2012 (Profitability)
2012 (Valuation)
2012 (Operations)
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
CSLBaxter
InternationalSanofi Grifols
Industry Median
Market Median1
Current Ratio 3.6 1.95 1.65 3.26 3.03 1.47
Quick Ratio 1.74 1.2 1.01 1.55 2.46 5.32
Leverage Ratio 1.99 2.94 1.75 3 2.07 5.34
Total Debt/Equity 0.57 <0.01 0.25 1.07 0.63 0.88
Interest Coverage 31.76 25.35 9.59 2.88 9.45 5.29
CSLBaxter
InternationalSanofi Grifols
Industry Median
Market Median1
Revenue Per Share $11.11 $25.99 $17.07 $10.71 $1.20 $5.20
Dividend Per Share $0.70 $1.84 $1.00 $0.21 -- --
Cash Flow Per Share $2.94 $5.15 $2.93 $2.29 -- --
Working Capital Per Share $5.42 $8.29 $3.36 $5.29 $3.35 $2.60
Long-Term Debt Per Share $3.91 $10.28 $4.02 $7.33 $0.05 $0.09
Book Value Per Share $6.93 $13.42 $28.10 $7.64 $4.89 $15.72
Total Assets Per Share $13.78 $37.57 $37.69 $22.21 $9.61 $89.25
2012 (Financial)
2012 (Per Share Data)
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
IT Infrastructure
Other Technology
Deltatec
Ascom Network
ElasticPath
Twiki Web 2.0
PAS-X
Surveygizmo
ERP
Oracle Fatwire
SAP R/3
WBS Chart Pro
TrackWise
Pilgrim SmartPulse
Oracle Fatwire
SAP R/3
WBS Chart Pro
TrackWise
Pilgrim SmartPulse
Database
MS SQL Server
Programming Language
jQuery
Network
Citrix Netscaler
CheckPoint
WebServer
Google Analytics
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Total IT Employees
Total Servers
Physical Servers
Virtual Servers
Total Pc’s
Desktop PC’s
Portable Pc’s
Total Printers
Total Network Devices
Total Phone Lines
Total Enterprise Storage Capacity (Tb)
250+
200+
--
3000+
1400+
--
2000+
500+
200
Total IT Budget
Communications
Storage Device
Hardware
Software
Services & Outsourcing
Other Miscellaneous
IT Budget per IT Employee
IT Budget as percentage of revenue
Over 30M+
$1.24M
$300,000
$400K
$522.14K
$738.00K
$10,000
$15K
3 - 5%
Estimated IT Footprint Estimated IT Budget
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Executive Management Biographies
Paul PerreaultChief Executive Officer & Managing Director
Paul PerreaultBA Psychology – (Age 55)
International Pharmaceutical Industry (Resident in Pennsylvania, USA)Independent: No
Chief Executive Officer and Managing DirectorMr Perreault was appointed to the CSL Board in February 2013 and is the Chief Executive Officer and Managing Director. Paul joined a CSLpredecessor company in 1997 and prior to his current appointment was President, CSL Behring. Paul’s previous roles were in sales, marketingand operations. He has worked in senior leadership roles with Wyeth, Centeon, Aventis Behring, Aventis Bioservices and CSL. Paul has worked inthe health care field for 30 years.
Mr Perreault is a member of the Innovation and Development Committee.
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Gordon Naylor,Chief Financial Officer
Gordon was appointed Chief Financial Officer in October 2010. Hejoined CSL in 1987 and has held many operational and corporateroles in different parts of the CSL Group. Prior to his current role,Gordon was based in the US and responsible for CSL Behring’s globalsupply chain, the supply of plasma for CSL Behring and CSL’s globalinformation systems.
Andrew Cuthbertson,R&D Director and Chief Scientific Officer
Andrew is responsible for CSL’s Research and Development strategyand the implementation of that strategy. He joined CSL in March1997 as Director of Research. Andrew trained in medicine andscience at the University of Melbourne, the Walter and Eliza HallInstitute, the Howard Florey Institute and the National Institutes ofHealth in the US. Andrew was then a Senior Scientist at Genentech,Inc. in San Francisco.
Mary Sontrop,Executive Vice President, Manufacturing and Planning
Mary was appointed as Executive Vice President, CSL BehringOperations in April 2010. She joined CSL as a Production Manager inApril 1988 and has held a broad range of positions in manufacturing,quality management and general management located in Australia,Switzerland and Germany. Prior to her current position, Mary wasGeneral Manager of CSL Biotherapies for Australia and New Zealand.
Karen Etchberger,EVP, Quality and Business Services, CSL Behring
Karen was appointed as Executive Vice President, Plasma, SupplyChain and Information Technology in April 2010. She joined CSL asProduct Manager in JRH Biosciences in August 2001 and progressedthrough a number of positions in technical services, qualitymanagement, research and development, and was most recentlyHead of Global Quality for CSL Behring. Prior to joining CSL, Karenwas Director of Developmental Research at Endotech Corporation.
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Greg Boss,EVP, Legal, CSL Behring & CSL Group General Counsel
Greg was appointed Group General Counsel in January 2009 and isresponsible for worldwide legal operations for all CSL Groupcompanies. He joined CSL in 2001, serving as General Counsel forCSL Behring, a position he continues to hold. In addition, Greg isresponsible for risk management for the Group. Prior to joining CSL,Greg was Vice President and Senior Counsel for CB Richard EllisInternational.
Jill Lever,SVP, Human Resources
Jill joined CSL Limited as Senior Vice President, Human Resources in2009. She heads the Human Resources function and works with theManaging Director and Board on strategic matters relating to talent,succession, organisation culture and executive remuneration.Originally from the UK, Jill held a number of Human Resources roleswith the Royal Dutch Shell Group in Europe, the Middle East, SouthAmerica and Asia Pacific before working in the finance and miningsectors in Melbourne.
Ingolf Sieper,EVP, Worldwide Commercial Operations, CSL Behring
Ingolf was appointed Executive Vice President, Worldwide Commercial Operations, CSL Behring in 2011. He is responsible for all sales andmarketing activities globally for CSL Behring. Ingolf joined CSL Behring in 1986 and has a strong background in marketing and management inthe coagulation, diagnostic and plasma protein divisions. Among the roles in which he has served, Ingolf was Vice President and GeneralManager, Commercial Operations, Central Europe, with responsibility for CSL Behring’s commercial activities in Germany, Switzerland, Austriaand Slovenia.
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Board of Directors Biographies
John Shine,Chairman
John ShineBSc (Hon), PhD, DSc, FAA - (Age 66)
Pharmaceutical Industry and Medicine (Resident in NSW)Independent: Yes
ChairmanProfessor Shine was appointed to the CSL Board in June 2006. He is Professor of Molecular Biology and Professor of Medicine at the Universityof NSW, and a Director of many scientific research and medical bodies throughout Australia. Professor Shine is President of the Museum ofApplied Arts and Science (Powerhouse Museum and Sydney Observatory) and was formerly Executive Director of the Garvan Institute of MedicalResearch. He was also formerly Chairman of the National Health and Medical Research Council and a Member of the Prime Minister’s Science,Engineering and Innovation Council. In November 2010, he was awarded the 2010 Prime Minister's Prize for Science.
Professor Shine is a member of the Innovation and Development Committee.
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
John Akehurst
John AkehurstMA (Oxon), FIMechE - (Age 63)
Engineering and Management (Resident in Western Australia)Independent: Yes
Mr Akehurst was appointed to the CSL Board in April 2004. He had30 years’ executive experience in the international hydrocarbonindustry, including seven years as Managing Director and CEO ofWoodside Petroleum Ltd. Mr Akehurst is a member of the Board ofthe Reserve Bank of Australia and is also a Director of Origin EnergyLimited, Securency International Pty Ltd and Transform Pty Ltd. Hewas formerly Chairman of Alinta Limited and of Coogee ResourcesLimited and is a former Director of Oil Search Limited. Mr Akehurst isChairman of the National Centre for Asbestos Related Diseases andthe Fortitude Foundation and a Director of the University of WesternAustralia’s Business School.
Mr Akehurst is a member of the Human Resources and RemunerationCommittee.
David Anstice
David AnsticeBEc - (Age 64)
International Pharmaceutical Industry(Resident in Pennsylvania,USA)Independent: Yes
Mr Anstice was appointed to the CSL Board in September 2008. MrAnstice was a long-time member of the Board of Directors andExecutive Committee of the US Biotechnology Industry Organisation,and has over 40 years’ experience in the global pharmaceuticalindustry. Until August 2008, Mr Anstice was for many years a seniorexecutive of Merck & Co. Inc. serving at various times as President ofMerck Human Health for US/Canada/Latin America, Europe, Japanand Asia, and upon retirement was an Executive Vice President. He isa Director of Alkermes Plc, Dublin, Ireland and a Director of theUnited States Studies Centre at the University of Sydney.
Mr Anstice is a member of the Human Resources and RemunerationCommittee and the Innovation and Development Committee.
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Bruce Brook
Bruce BrookBCom, BAcc, FCA, MAICD - (Age 57)
Finance and Management (Resident in Victoria)Independent: Yes
Mr Brook was appointed to the CSL Board in August 2011. He iscurrently Chairman of Programmed Maintenance Services Limited anda Director of Boart Longyear Limited and Newmont MiningCorporation. Mr Brook has previously been Chairman of EnergyDevelopments Limited and a Director of Lihir Gold Limited andConsolidated Minerals Limited. During his executive career he wasChief Financial Officer of WMC Resources Limited and prior to that theDeputy Chief Financial Officer of the ANZ Banking Group.
Mr Brook is a member of the Audit and Risk Management Committee.
Christine O’Reilly
Christine O’ReillyBBus (Age 51)
Finance and Infrastructure (Resident in Victoria)Independent: Yes
Ms O’Reilly was appointed to the CSL Board in February 2011. Sheis a Director of the Transurban Group and Care Australia. During herexecutive career, she was Co-Head of Unlisted InfrastructureInvestments at Colonial First State Global Asset Management andprior to that was the Chief Executive Officer of the GasNet AustraliaGroup.
Ms O’Reilly is a member of the Audit and Risk ManagementCommittee and the Human Resources and Remuneration Committee.
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Ian Renard
Ian RenardBA, LLM, LLD (Hon), FAICD - (Age 66)
Law (Resident in Victoria)Independent: Yes
Mr Renard was appointed to the CSL Board in August 1998. Formany years he practised in company and commercial law and is aformer Chancellor of the University of Melbourne. Mr Renard is aDirector of SP AusNet (a listed entity which comprises two companiesand a trust), Hillview Quarries Pty Ltd and Peninsula WasteManagement Pty Ltd. He is the Chairman of the University ofMelbourne Archives Advisory Board and is Chairman of the R E RossTrust.
Mr Renard is Chairman of the Audit and Risk ManagementCommittee.
Maurice Renshaw
Maurice RenshawB.Pharm. - (Age 65)
International Pharmaceutical Industry (Resident in NSW)Independent: Yes
Mr Renshaw was appointed to the CSL Board in July 2004.Formerly, he was Vice President of Pfizer Inc, USA, Executive VicePresident, Pfizer Global Consumer Group and President of Pfizer’sGlobal Consumer Healthcare Division. Prior to his positions in Pfizer,Mr Renshaw was Vice President of Warner Lambert Co. and Presidentof Parke-Davis USA. He has had more than 35 years’ experience inthe international pharmaceutical industry.
Mr Renshaw is Chairman of the Innovation and DevelopmentCommittee.
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Organizational Chart
Executive Management
Gordon Naylor,Chief Financial [email protected]
Andrew Cuthbertson,R&D Director & Chief Scientific [email protected]
Mary Sontrop,EVP, Manufacturing and [email protected]
Ingolf Sieper,EVP, WW Commercial Operations, CSL Behring
Karen Etchberger,EVP, Quality & Business Services, CSL Behring
Jill Lever,Senior Vice President, Human [email protected]
Paul Perreault,Chief Executive Officer & Managing [email protected]
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Contact Name Title Email Id Social Media
Aaron Stritthof Contracting Project Manager [email protected]
Adele Mount NHMRC Industry Fellow [email protected]
Adrian Zuercher Head of Immunoglobulins Research [email protected]
Andrew White Manager, Technology Transfer [email protected]
Ashleigh Everett IT Senior Project Manager [email protected]
Ben Rushbrook Corporate HR Programs Analyst [email protected]
Benson Lee Sales Training Manager [email protected]
Beth Healy Senior RA Manager [email protected]
Brent McKenzie Director. In-vivo Biology [email protected]
Christine Wichems Director, Medical Writing and Disclosure [email protected]
Connie Costanzo Facility Validation Manager [email protected]
Darren Harris Validation Manager [email protected]
David Glover Senior Director, Bioprocess Development [email protected]
David Plant Principal Regulatory Affairs Associate [email protected]
Di Goodall Senior Scientist Supervisor [email protected]
Dimce Dimovski Production Technician [email protected]
Esther Huai-Yian Ling Scientist [email protected]
Evelyn Brandt Regulatory Affairs Manager [email protected]
Jagdev Sidhu Sr Director Clinical Pharmacology & Pharmacometrics [email protected]
Jenny Chia Research Scientist [email protected]
Contacts
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Contact Name Title Email Id Direct Dial Social Media
Debbie Drane SVP, Research and Development [email protected] +61-393891902
Andrew Nash Senior Vice President, Research [email protected] +61-393892034
Fatima Landim Project Manager [email protected] --
Frank Albano Global Project Lead [email protected] +61-393891434
Gail James Senior Brand Manager (contract) [email protected] --
Helen Concilia Marketing Director [email protected] +61-393892741
Ian Ives Director, Transhipping Operations [email protected] +61-294327512
Ingo Brand Scientist [email protected] --
Irina Staxen Director Fermentation Development [email protected] --
Jane Leong VP, Scientific Affairs [email protected] +61-393891175
Jemimah Pentland Senior Manager, Communications [email protected] --
Jill Lever Senior Vice President Human Capital [email protected] --
Jim Karagaslis IT Quality - Risk and Audit [email protected] --
John Beman Sr Manager, Quality Monitoring & Review [email protected] --
Julian Keane Sr Manager, Biomanufacturing Projects [email protected] --
Karen Gardner Sr Director, Clinical Shared Services [email protected] --
Karen Spencer Project Engineer [email protected] --
Katie Wood Mechanical Engineer [email protected] --
Kenny Ng Helpdesk Specialist [email protected] --
Lachlan Cruise Sr Manager, Demand & Operations Planning [email protected] --
Contacts
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Contact Name Title Email Id Social Media
Louis Fabri Director Protein technologies [email protected]
Lynda Allan Virology Scientist [email protected]
Magnus Schroeder Sr Scientist Supervisor, Purification Development [email protected]
Marilyn Clarke QC Immunochemistry Manager [email protected]
Marita Harris HR Advisor [email protected]
Mark DeWitte Director Clinical Haematology / Oncology [email protected]
Martin Pearse Principal Scientist [email protected]
Mary-Jane O'Sullivan Area Business Manager - Vaccines mary-jane.o'[email protected]
Matthias Zimmermann Senior Scientist Supervisor [email protected]
Metani Rooms Senior Business Development Manager [email protected]
Michael Fugaro Server & Network Operations Manager [email protected]
Michael Wilson Senior Director, Head of Molecular Biology [email protected]
Natasha Walker HR Business Partner [email protected]
Nick Wilson Senior Scientist [email protected]
Patrick Castauro Senior Manager, Corporate Responsibility [email protected]
Paul Davies Director, R&D Strategy & Portfolio Analytics [email protected]
Paul Smrdelj Manager, Bioanalytical Sciences [email protected]
Peter Larsen Group Manager Taxation [email protected]
Phil Keep Vice President Intellectual Property [email protected]
Purush Devanathan Validation Specialist [email protected]
Contacts
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Contact Name Title Email Id Social Media
Rachel Jensen Strategic Compliance Improvement [email protected]
Rachel Mansfield Change Manager [email protected]
Rick Haydon Associate Brand Manager ,CSL Biotherapies [email protected]
Rose Fida Program Manager, Development [email protected]
Roslyn Davis Senior Scientist Supervisor [email protected]
Sabine Rauth Research Scientist, Antibody Technologies Division [email protected]
Sharon Davoli HR Business Partner [email protected]
Stephen Pickering Automation Project Engineer [email protected]
Steve Honey Director, Product Development Projects & Tech Transfer [email protected]
Susan Henderson Sr IT Project Manager - Special Projects [email protected]
Thalia Keller HR Generalist [email protected]
Tim Green Director; Clinical & Translational Science Department [email protected]
Tracey Sleet Learning and Development Specialist [email protected]
Travis Newing Quality Management Delegate - Australia [email protected]
Tricia Stewart Senior Director, Quality [email protected]
Wallace Williams SAP Business Analyst [email protected]
Contacts
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Key Benefits
1. Key benefits of buying this profile include,
2. You get detailed information about the company and its operations to identify potential customers and suppliers.
3. The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, keyexecutives and their biographies and key competitors.
4. Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on themajor developments affecting the company.
5. The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively.Recent developments in the company covered in the profile help you track important events.
6. Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
7. Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/ortechnological threats are highlighted.
8. Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operationalperformance.
9. Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns,liquidity and leverage, financial position and efficiency ratios.
10. Gain key insights into the company for academic or business research.
11. Key elements such as SWOT analysis, corporate strategy and financial ratios and charts, Website Analysis are incorporated in the profile toassist your academic or business research needs.
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts
Terms & Conditions
1. The information contained in this report is exclusively provided to you for your own use and may not be transferred to any other party. Bynecessity, credit decisions must be based on the credit provider's policies as applied to each unique transaction. In no event, should theinformation contained in this report be used as the sole source in making a credit decision. 360° Profiles expressly disclaims all warrantiesassociated with the provision of this information, and makes no representations as to the accuracy or timeliness. In all events, 360° Profile’sliability shall be limited to the amount actually received by it on account of the provision of this report.
2. Due to changes occurring every day, this information is believed to be accurate but is not guaranteed.
3. It is a violation of both federal and state law to transmit an unsolicited advertisement to a facsimile.
4. machine. Any person violating such laws may be subject to civil and criminal penalties which may exceed $500 for each transmission of anyunsolicited facsimile. We provide business information for lawful purposes and expressly forbid the use of our business information in anyunlawful manner. Reselling the document is strictly against the Law.
5. Contacts, Email Addresses and Social Media Links are 100% verified on the date of report creation, they should be used with in LicensingPeriod only.
6. Data Format will be provided in PDF Format Only in Order to prevent misusage of content/Design.
7. Report Prepared Date : August 2013
8. All Data’s are Pulled as per the terms and condition agreed in Work Order Only
9. All Data’s are Pulled from Highly Paid Subscription Data vendors and Web Research Only
IT Infrastructure
Worldwide Locations
Executive Management Biographies
Financial Analysis
Board of Directors Biographies
SWOT Analysis
Organizational Chart
Competitors AnalysisFirmographic
Contacts